FOXP3

Forkhead box P3
Identifiers
Symbols FOXP3; AIID; DIETER; IPEX; MGC141961; MGC141963; PIDX; XPID
External IDs OMIM300292 MGI1891436 HomoloGene8516 GeneCards: FOXP3 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 50943 20371
Ensembl ENSG00000049768 ENSMUSG00000039521
UniProt Q9BZS1 Q53Z59
RefSeq (mRNA) NM_001114377.1 NM_054039
RefSeq (protein) NP_001107849.1 NP_473380
Location (UCSC) Chr X:
49.11 – 49.12 Mb
Chr X:
7.16 – 7.17 Mb
PubMed search [1] [2]

FOXP3 (forkhead box P3) is a protein involved in immune system responses. A member of the FOX protein family, FOXP3 appears to function as a master regulator in the development and function of regulatory T cells.[1]

While the precise control mechanism has not yet been established, FOX proteins belong to the forkhead/winged-helix family of transcriptional regulators and are presumed to exert control via similar DNA binding interactions during transcription.

Contents

Structure

The human FOXP3 genes contain 11 coding exons. Exon-intron boundaries are identical across the coding regions of the mouse and human genes. By genomic sequence analysis, the FOXP3 gene maps to the p arm of the X chromosome (specifically, Xp11.23).[2][3]

Physiology

The discovery of Foxp3 as a specific marker of natural T regulatory cells (nTregs, a lineage of T cells) and adaptive/induced T regulatory (a/iTregs) T cells gave a molecular anchor to the population of regulatory T cells (Tregs), previously identified by non-specific markers such as CD25 or CD45RB.[4][5][6] In animal studies, Tregs that express Foxp3 are critical in the transfer of immune tolerance, especially self-tolerance, so that hopefully in the future this knowledge can be used to prevent transplant graft rejection. The induction or administration of Foxp3 positive T cells has, in animal studies, led to marked reductions in (autoimmune) disease severity in models of diabetes, multiple sclerosis, asthma, inflammatory bowel disease, thyroiditis and renal disease.[7] These discoveries give hope that cellular therapies using Foxp3 positive cells may, one day, help overcome these diseases. Unfortunately recent T cell biology investigations revealed that T cell nature is much more plastic than initially thought. Thus the regulatory T cell therapy may in fact be very risky as the T regulatory cell transferred to the patient may reverse and become another proinflammatory T cell.(see recent papers from Romagnani, Stockinger etc.). Th17 (T helper 17) cells are proinflammatory and are produced under very similar environments as a/iTregs. Th17 cells are produced under the influence of TGF-β and IL-6 (or IL-21) whereas a/iTregs are produced under the influence of solely TGF-β and as such the difference between a proinflammatory and a pro-regulatory scenario is the presence of a single interleukin (IL-6 or IL-21 is being debated by immunology laboratories as the definitive signaling molecule). It seems so far that murine studies point to IL-6 whereas human studies have shown IL-21 (Citation needed).

Pathophysiology

In human disease, alterations in numbers of regulatory T cells – and in particular those that express Foxp3 – are found in a number of disease states. For example, patients with tumors have a local relative excess of Foxp3 positive T cells which inhibits the body's ability to suppress the formation of cancerous cells.[8] Conversely, patients with an autoimmune disease such as systemic lupus erythematosus (SLE) have a relative dysfunction of Foxp3 positive cells.[9] The Foxp3 gene is also mutated in the X-linked IPEX syndrome (Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-linked).[10] These mutations were in the forkhead domain of FOXP3, indicating that the mutations may disrupt critical DNA interactions.

In mice, a Foxp3 mutation (a frameshift mutation that result in protein lacking the forkhead domain) is responsible for 'Scurfy', an X-linked recessive mouse mutant that results in lethality in hemizygous males 16 to 25 days after birth.[11] These mice have overproliferation of CD4+ T-lymphocytes, extensive multiorgan infiltration, and elevation of numerous cytokines. This phenotype is similar to those that lack expression of CTLA-4, TGF-β, human disease IPEX, or deletion of the Foxp3 gene in mice ("scurfy mice"). The pathology observed in scurfy mice seems to result from an inability to properly regulate CD4+ T-cell activity. In mice overexpressing the Foxp3 gene, fewer T cells are observed. The remaining T cells have poor proliferative and cytolytic responses and poor interleukin-2 production, although thymic development appears normal. Histologic analysis indicates that peripheral lymphoid organs, particularly lymph nodes, lack the proper number of cells.

See also

References

  1. ^ Zhang L, Zhao Y (June 2007). "The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road". J. Cell. Physiol. 211 (3): 590–597. doi:10.1002/jcp.21001. PMID 17311282. 
  2. ^ Bennett CL, Yoshioka R, Kiyosawa H, Barker DF, Fain PR, Shigeoka AO, Chance PF (February 2000). "X-Linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3". Am. J. Hum. Genet. 66 (2): 461–468. doi:10.1086/302761. PMC 1288099. PMID 10677306. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1288099. 
  3. ^ Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (January 2001). "Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse". Nat. Genet. 27 (1): 68–73. doi:10.1038/83784. PMID 11138001. 
  4. ^ Hori S, Nomura T, Sakaguchi S (2003). "Control of regulatory T cell development by the transcription factor Foxp3". Science 299 (5609): 1057–1061. doi:10.1126/science.1079490. PMID 12522256. 
  5. ^ Fontenot JD, Gavin MA, Rudensky AY (2003). "Foxp3 programs the development and function of CD4+CD25+ regulatory T cells". Nature Immunology 4 (4): 330–336. doi:10.1038/ni904. PMID 12612578. 
  6. ^ Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY (2005). "Regulatory T cell lineage specification by the forkhead transcription factor Foxp3". Immunity 22 (3): 329–341. doi:10.1016/j.immuni.2005.01.016. PMID 15780990. 
  7. ^ Suri-Payer E, Fritzsching B (2006). "Regulatory T cells in experimental autoimmune disease". Springer Semin Immunopathol 28 (1): 3–16. doi:10.1007/s00281-006-0021-8. PMID 16838180. 
  8. ^ Beyer M, Schultze J (2006). "Regulatory T cells in cancer". Blood 108 (3): 804–811. doi:10.1182/blood-2006-02-002774. PMID 16861339. 
  9. ^ Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda A, González-Amaro R (2006). "Regulatory T cells in patients with systemic lupus erythematosus". J Autoimmun 27 (2): 110–118. doi:10.1016/j.jaut.2006.06.005. PMID 16890406. 
  10. ^ Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L, Kelly T, Saulsbury F, Chance P, Ochs H (2001). "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3". Nat Genet 27 (1): 20–21. doi:10.1038/83713. PMID 11137993. 
  11. ^ Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S, Wilkinson J, Galas D, Ziegler S, Ramsdell F (2001). "Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse". Nat Genet 27 (1): 68–73. doi:10.1038/83784. PMID 11138001. 

Further reading

External links